Nutraceuticals and Drug Treatment in Frail Older Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

485 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-01

Study Completion Date

2023-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Frailty is a multidimensional condition due to reserve loss leading to physical and cognitive impairment that is very common in older adults; in fact, its incidence increases with age. Frail older adults present a high risk of adverse events such as disability, hospitalization and mortality. It is very important to check comorbidities and complications to reduce the incidence of cognitive and physical impairment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nutrition and Frailty in Older Persons

NCT01433211

Frailty

COMPLETED

Successful Aging and Frailty

NCT03963050

Frailty Syndrome Cognitive Impairment Sarcopenia

UNKNOWN NA

Prevalence, Determinants and Natural History of Frailty and Pre-frailty in Elderly People

NCT04518423

Frailty Frailty Syndrome Frail Elderly Syndrome +5 more

RECRUITING

Nutritional Programme for Dementia Elderly Patient

NCT00479843

Alzheimer's Disease Dementia

COMPLETED NA

Prevalence of Sarcopenia and Its Geriatric Features

NCT02664376

Sarcopenia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Frailty is a multidimensional condition due to reserve loss leading to physical and cognitive impairment that is very common in older adults; in fact, its incidence increases with age. Frail older adults present a high-risk of adverse events such as disability, hospitalization and mortality. It is very important to check comorbidities and complications to reduce the incidence of cognitive and physical impairment; hence, clinical evaluation is the main goal to get an early diagnosis and a timely treatment for cognitive impairment. Considering this background, the study will investigate the effects of nutraceuticals and drug treatment on cognitive impairment in frail older adults. In this scenario, global cognitive function will be evaluated with Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) test and physical impairment with the Fried criteria and 5-metres gait speed test.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Frailty

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Frail older adults treated with nutraceuticals and drugs

Nutraceuticals

Intervention Type OTHER

To observe the effect on cognitive and physical impairment.

Frail older adults not treated with nutraceuticals and drugs

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nutraceuticals

To observe the effect on cognitive and physical impairment.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

empaglifozin nebivolol sertraline rivastigmine metformin ramipril amlodipine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \> 65 years;
* a frailty status.

Exclusion Criteria

* age \< 65 years.
* no frailty status.
* left ventricular ejection fraction \<25%, with previous myocardial infarction or previous PPCI or/and coronary by-pass grafting.

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No